Molecular Medicine Laboratory, Unidad Academica de Medicina Humana y Ciencias de la Salud, Universidad Autonoma de Zacatecas, Campus UAZ siglo XXI, Carretera Zacatecas-Guadalajara Km 6, Ejido la Escondida, 98160 Zacatecas, Mexico.
Instituto Tecnologico de Estudios Superiores Monterrey, Campus Monterrey, Avenida Ignacio Morones Prieto 3000 Poniente, Los Doctores, 64710 Monterrey, Nuevo Leon, Mexico.
Pregnancy Hypertens. 2019 Apr;16:120-125. doi: 10.1016/j.preghy.2019.03.012. Epub 2019 Mar 28.
Preeclampsia pathogenesis involves imbalances of oxidative stress networks including the heat shock protein (HSP) pathway. Micro-RNAs regulate gene networks associated with preeclampsia. Hsp90 and Runx2 are transcriptional targets of miR-628-3p. Considering that potential participation of hsa-miR-628-3p in PE development is still not elucidated, the aim of this study was to evaluate serum microRNA expression of hsa-miR-628-3p and hsa-miR-628-5p and their association with the preeclampsia development.
A retrospective nested cohort case-control study was conducted. Serum samples from 16 pregnant women who developed preeclampsia (WWD-PE) during the follow-up period were selected and individually matched to that from 18 women in the cohort who had healthy pregnancies without complications (controls).
The levels of hsa-miR-628-3p and hsa-miR-628-5p were measured in serum samples from study groups at 12, 16, and 20 weeks of gestation (WG) using TaqMan probes. Additionally serum levels were measured at the moment of diagnosis, in women with preeclampsia.
Serum levels of hsa-miR-628-3p were higher than controls in WWD-PE at 12 WG (RQ = 7.7; P = 0.020), and of hsa-miR-628-5p at 20 WG (RQ = 3.4; P = 0.008). An increase in hsa-miR-628-3p serum levels at 12 WG (RQ = 12.01; P = 0.001) and of hsa-miR-628-5p at 20 WG (RQ = 2.95; P = 0.033) was also observed in women who developed mild preeclampsia, and severe preeclampsia, respectively.
Serum hsa-miR-628-3p and hsa-miR-628-5p were differentially expressed between WWD-PE and controls, suggesting a participation of these miRNAs in the development of preeclampsia. Future studies are needed to validate hsa-miR628-3p and -5p as early predictors of preeclampsia.
子痫前期的发病机制涉及氧化应激网络的失衡，包括热休克蛋白（HSP）途径。微小 RNA 调节与子痫前期相关的基因网络。Hsp90 和 Runx2 是 miR-628-3p 的转录靶标。鉴于 hsa-miR-628-3p 可能参与子痫前期的发展仍未阐明，本研究旨在评估血清 hsa-miR-628-3p 和 hsa-miR-628-5p 的微小 RNA 表达及其与子痫前期发展的关系。
进行了一项回顾性嵌套队列病例对照研究。从随访期间发生子痫前期（WWD-PE）的 16 名孕妇的血清样本中选择，并单独与队列中 18 名无并发症（对照组）健康妊娠的妇女的血清样本匹配。
使用 TaqMan 探针在研究组孕妇妊娠 12、16 和 20 周（WG）时测量血清中 hsa-miR-628-3p 和 hsa-miR-628-5p 的水平。此外，在子痫前期妇女确诊时测量血清水平。
WWD-PE 组孕妇在 12 WG 时血清 hsa-miR-628-3p 水平高于对照组（RQ=7.7；P=0.020），在 20 WG 时血清 hsa-miR-628-5p 水平高于对照组（RQ=3.4；P=0.008）。在分别发展为轻度子痫前期和重度子痫前期的孕妇中，也观察到血清 hsa-miR-628-3p 水平在 12 WG 时升高（RQ=12.01；P=0.001），血清 hsa-miR-628-5p 水平在 20 WG 时升高（RQ=2.95；P=0.033）。
WWD-PE 与对照组之间血清 hsa-miR-628-3p 和 hsa-miR-628-5p 表达存在差异，提示这些 miRNA 参与了子痫前期的发生。需要进一步的研究来验证 hsa-miR628-3p 和 -5p 是否可作为子痫前期的早期预测因子。
